Phase I/II study of VELCADE [bortezomib]-BEAM [carmustine + cytarabine + etoposide + melphalan] and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin's lymphoma, transformed or mantle cell lymphoma

Trial Profile

Phase I/II study of VELCADE [bortezomib]-BEAM [carmustine + cytarabine + etoposide + melphalan] and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin's lymphoma, transformed or mantle cell lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Bortezomib (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 01 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 06 May 2011 Planned End Date changed from 1 Jan 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top